Keith A. Meister

October 17, 2026

Illumina Launches BioInsight Platform Amid AI Drug Discovery Trends. Illumina introduced its BioInsight Platform, a new unified software environment designed to speed up genomic and multiomic research. This move aligns with broader industry trends, including the recent $150 million IPO of AI drug discovery firm Iambic. Analysts are currently evaluating whether the stock's current valuation reflects these strategic shifts in AI and diagnostics.

October 13, 2026

GeneDx Shares New Genomic Newborn Screening Data. GeneDx presented new evidence for its genomic newborn screening program at the ICoNS 2026 conference. This update highlights the company's ongoing development in clinical genomics. The stock is currently trading near its 52-week low, with an average analyst target of $93.50.

October 5, 2026

MGM Resorts stock drops after Diller deal collapse. MGM Resorts shares fell following the collapse of a deal with Diller. This event has pushed the stock into oversold territory, with the RSI at 13.8. The current price is near the $46.53 support level, which has been tested 11 times. The average analyst price target remains at $49.33.

October 13, 2026

Vestis Names New CFO, Could Alter Turnaround Strategy. Vestis Corporation has appointed a new chief financial officer, a move that may change the company’s approach to its turnaround plan. The hire signals a possible shift in how the firm will manage costs and growth, which could affect its financial outlook. The stock is trading near a key support level of $12.78, and analysts expect a target of $13.00 on average. This development is noteworthy for stakeholders watching the company’s recovery path.